PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation

Peifang Xu1,2,3*, Liping Jiang2*, Yang Yang4*, Mengge Wu2, Baiyang Liu2,3, Yulin Shi2,3, Qishuo Shen2,4, Xiulin Jiang2,3, Yaomei He2,3, Dating Cheng5, Qiuxia Xiong5, Zuozhang Yang5, Lincan Duan5, Jie Lin5, Song Zhao4, Peng Shi6,7, Cuiping Yang2,5, Yongbin Chen2,7*

1. School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
2. Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Kunming, Yunnan 650223, China.
3. Kunming College of Life Science, University of Chinese Academy of Sciences, Beijing, 100049, China.
4. Department of Thoracic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
5. Kunming Medical University, Kunming 650223, China.
6. State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China.
7. Center for Excellence in Animal Evolution and Genetics, Chinese Academy of Sciences, Kunming, Yunnan 650223, China.

*These authors contributed equally to this work.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.12.17; Accepted: 2020.01.20; Published: 2020.02.19

Abstract

Purpose: Lung cancer is the leading cause of cancer related deaths worldwide. We have previously identified many differentially expressed genes (DEGs) from large scale pan-cancer dataset using the Cross-Value Association Analysis (CVAA) method. Here we focus on Progestin and AdipoQ Receptor 4 (PAQR4), a member of the progestin and adipocytokine receptor (PAQR) family localized in the Golgi apparatus, to determine their clinical role and mechanism in the development of non-small cell lung cancer (NSCLC).

Methods: The protein expression profile of PAQR4 was examined by IHC using tissue microarrays, and the effects of PAQR4 on cell proliferation, colony formation and xenograft tumor formation were tested in NSCLC cells. Real-time RT-PCR, co-immunoprecipitation (co-IP) and GST-pulldown assays were used to explore the mechanism of action of PAQR4.

Results: We provided evidence showing that PAQR4 is increased in NSCLC cancer cell lines (A549, H1299, H1650, H1975, H358, GLC-82 and SPC-A1), and identified many mutations in PAQR4 in non-small cell lung cancer (NSCLC) tissues. We demonstrated that PAQR4 high expression correlates with a worse clinical outcome, and that its knockdown suppresses cell proliferation by inducing apoptosis. Importantly, overexpressed PAQR4 physically interacts with Nrf2 in NSCLC cells, blocking the interaction between Nrf2 and Keap1.

Conclusion: Our results suggest that PAQR4 depletion enhances the sensitivity of cancerous cell to chemotherapy both in vitro and xenograft tumor formation in vivo, by promoting Nrf2 protein degradation through a Keap1-mediated ubiquitination process.

Key words: Progestin and AdipoQ Receptor 4, non-small cell lung cancer, Nrf2, Keap1, ubiquitination

Introduction

Lung cancer is the predominant cause of cancer related deaths [1]. Within the main types of lung cancers, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), NSCLC accounts for approximately 85% of all lung cancer, with a poor 5-year survival of only ~15%. NSCLC includes lung adenocarcinoma (ADC), lung squamous cell carcinoma (SCC) and large-cell lung carcinoma [1].
Despite the huge advances in treatment options including surgery, chemotherapy, radiation and targeted therapies, prognosis remains poor because of the presence of locally advanced metastatic tumors in most patients at the time of diagnosis [2]. NSCLC patients are treated uniformly with a one-size-fits-all approach - Platinum-based chemotherapy, where cisplatin or carboplatin is used in combination with gemcitabine, vinorelbine, pemetrexed or taxanes (docetaxel or paclitaxel) [3]. However, patients may also benefit from other therapeutic approaches that involve interr uptions of essential signaling pathways important for NSCLC development and progression. Clinical trials with tyrosine kinase inhibitors (TKIs) targeted to mutant EGFR or ALK-fusion proteins, show a significant increase of the 5-year survival rate of NSCLC. Importantly, most patients with NSCLC are sensitive to chemotherapy at the early stage, but show drug resistance in the late stage, and the occurrence of inevitable drug resistance requires the identification of novel targets and the development of personalized medicine in future [4, 5].

After decades of research, various cancer cell intrinsic drug resistance mechanisms have been identified, e.g., activation of multidrug-resistance (MDR)-associated protein transporters, resistance to apoptosis or senescence signaling pathways and altered expression of detoxifying enzymes [6-9]. In particular, the overexpression of glutathione S-transferases (GSTs) may reduce the reactivity of various anticancer drugs [10]. The increase of GST levels is regulated by transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2). Nrf2 is a master transcriptional activator that drives the cellular response to combat a variety of stresses including oxidative stress, proteotoxic stress and electrophilic insults [11-14]. Under basal conditions, Nrf2 is constantly ubiquitinated by Keap1 (Kelch-like ECH-associated protein 1) and degraded through the proteasome pathway [11]. Exposure of cells to oxidative stress and electrophilic insult inactivates Keap1 and stabilizes Nrf2. Nrf2 then translocates into the nucleus and binds to the ARE (antioxidant response element), activating the transcription of many cytoprotective genes that encode detoxifying enzymes and antioxidant proteins [13]. The induction of these genes confers resistance against xenobiotic and oxidative stresses. Recently, the constitutive stabilization of Nrf2 was found in various human cancers [15-19], and cancers with high Nrf2 levels are associated with poor prognosis [17, 18]. Consistently, the role of Nrf2 in determining the efficacy of cisplatin was also demonstrated in ovarian cancer [20]. Moreover, many Keap1 mutations or loss of heterozygosity in the Keap1 locus has been identified in lung cancer [6]. Therefore, identification of new factors involved in Keap1-Nrf2 signaling pathways may benefit NSCLC patients with drug resistance in future.

We recently used a new method, Cross-Value Association Analysis (CVAA), to analyze the pan-cancer dataset, and identified numerous new differentially expressed genes (DEGs) [21], including Progesterin and AdipoQ Receptor 4 (PAQR4), a member of the progestin and adipoo receptor (PAQR) family, which includes 11 members (PAQR1 to PAQR11) in the human genome [22]. The conservation of the PAQR proteins between human and mouse orthologues is high [22]. The prototypes in this family are PAQR5-8 that function as membrane receptors for progesterone [23], as well as AdipoR1 and AdipoR2 (i.e., PAQR1 and PAQR2) are surface receptors for adiponectin and play important roles in metabolic regulation [24]. Especially, PAQR3, the closest homologue of PAQR4, has been recently discovered as a novel tumor suppressor deregulated in various types of human cancers including colon cancer, gastric cancer, bladder cancer, liver cancer, osteosarcoma, breast cancer, and laryngeal squamous cell carcinoma [25-30]. PAQR3 functions as a tumor suppressor mainly due to its negative regulation of the Ras/Raf/MEK/ERK signaling cascade [25]. Moreover, PAQR3 was identified as an adaptor protein that facilitates Keap1-Nrf2 complex formation leading to Nrf2 degradation and modulates antioxidant response [31]. Recent studies demonstrated that CDK4 protein level is controlled by the antagonistic actions between PAQR4 and SKP2, which contribute to the regulation of cell proliferation and tumorigenesis [32-34]. However, whether PAQR4 is involved in antioxidant or drug resistance functions in cancers remains elusive. In this study, we explored the potential antioxidant function of PAQR4 in NSCLC.

Results

PAQR4 is highly expressed in NSCLC

In our previous study, we developed a new method called CVAA (Cross-Value Association Analysis), which functions without a normalization and distribution assumption. We applied it to large-scale pan-cancer transcriptome data generated by The Cancer Genome Atlas (TCGA) project, and successfully discovered numerous new differentially expressed genes (DEGs) [21]. PAQR4 is one of these DEGs. It is a member of the PAQR family involved in the regulation of a number of biological processes including metabolism and cancer development [23-30]. To investigate the potential roles of PAQR4 in tumorigenesis, we examined its expression in various
cancer types using gene expression profiling interactive analysis [35], and found that PAQR4 is highly expressed in many cancer types (Figure S1A; Table 1). In addition, we surveyed PAQR4 protein expression in NSCLC (including lung SCC and ADC) and noncancerous control lung tissues (NCLT) by immunohistochemical staining (IHC) using a tissue microarray (Figure S1B-C; Table 2). The percentage of positive PAQR4 expression was significantly higher in ADC tissues (65.9%) than that in NCLT tissues (40.8%). Furthermore, we found that PAQR4 is upregulated in both lung adenocarcinoma and lung squamous cell carcinoma by UALCAN software (Figure 1A-B) [36].

**Table 1.** The abbreviation of cancer types used in supplementary Figure 1A.

| Abbreviation | Full name of cancer                  |
|--------------|-------------------------------------|
| BLCA         | Bladder urothelial carcinoma        |
| BRCA         | Breast invasive carcinoma           |
| COAD         | Colon adenocarcinoma                |
| HNSC         | Head and Neck squamous cell carcinoma|
| KICH         | Kidney Chromophobe                  |
| KIRC         | Kidney renal clear cell carcinoma   |
| KIRP         | kidney renal papillary cell carcinoma|
| LIHC         | Liver hepatocellular carcinoma      |
| LUAD         | Lung adenocarcinoma                 |
| LUSC         | Lung squamous cell carcinoma        |
| PRAD         | Prostate adenocarcinoma             |
| THCA         | Thyroid carcinoma                   |
| UCEC         | Uterine Corpus Endometrial Carcinoma|

![Figure 1. PAQR4 is highly expressed in NSCLC. (A-B) PAQR4 is highly expressed in lung adenocarcinoma-LUAD (A) and lung squamous cell carcinoma-LUSC (B). (C) PAQR4 high expression in NSCLC leads a significantly worse survival rate than its low expression patients. (D) PAQR4 is frequently mutated in NSCLC. Mutation: green; deletion: blue; amplification: red. (E) PAQR4 mRNA was increased in various NSCLC cell lines: A549, H1299, H1650, H1975, H358, GLC-82 and SPC-A1, compared with control cell line BEAS-2B. (F-G) Establishment of PAQR4 knockdown in SPC-A1 (F) and GLC-82 (G) cell lines and verified by real-time RT-PCR. (H-L) PAQR4 knockdown dramatically inhibits SPC-A1 cell proliferation (H), colony formation (I, J) and BrdU incorporation abilities (K, L). Means±SEM, * P <0.05; ** P <0.01; *** P <0.001; t-test. PQ4=PAQR4. sh#1=shRNA#1, sh#2=shRNA#2.](http://www.thno.org)
Table 2. Clinicopathological characteristics of patients with non-small cell lung cancer (NSCLC) and noncancerous lung tissues in the tissue arrays

| Characteristics | SCC (n=129) | ADC (n=129) |
|-----------------|-------------|-------------|
| Age(years)      | No. of patients (%) | Age(years) | No. of patients (%) |
| ≤50             | 31(24.0)    | ≤50         | 36(27.9)    |
| >50             | 98(76.0)    | >50         | 93(72.1)    |
| Gender          |             |             |
| Male            | 118(91.5)   | Male        | 76(58.9)    |
| Female          | 11(8.5)     | Female      | 53(41.1)    |
| Clinical stages |             |             |
| Stage I         | 29(22.5)    | Stage I     | 30(21.3)    |
| Stage II        | 29(22.5)    | Stage II    | 27(20.9)    |
| Stage III       | 63(48.8)    | Stage III   | 54(41.9)    |
| Stage IV        | 6(4.7)      | Stage IV    | 8(6.2)      |
| LNM status      |             |             |
| N0              | 57(44.2)    | N0          | 53(41.1)    |
| N1/N2/N3        | 72(55.8)    | N1/N2/N3    | 76(58.9)    |
| Differentiation |             |             |
| Well            | 3(2.3)      | Well        | 2(1.6)      |
| Moderate        | 56(43.4)    | Moderate    | 57(44.2)    |
| Poor            | 70(54.3)    | Poor        | 70(54.3)    |
| Survival status |             |             |
| Live            | 82(63.6)    | Live        | 74(57.4)    |
| Death           | 47(36.4)    | Death       | 55(42.6)    |

Non-cancerous lung tissues (n=49)

| Age (years) | Gender |
|-------------|--------|
| ≤50         | Male   | 39(79.6) |
| >50         | Female | 10(20.4) |

Next, we found that PAQR4 high expression correlates with a worse overall survival rate, using a Kaplan Meier plotter containing the affymetrix gene expression dataset for lung cancer (Figure 1C) [37]. Finally, to examine whether PAQR4 is also highly expressed in NSCLC cancerous cells, we analyzed its relative mRNA expression in normal human bronchial epithelium cell line (BEAS-2B) and NSCLC cancerous cell lines (A549, H1299, H1650, H1975, H358, GLC-82 and SPC-A1). Consistent with our findings in the database (Figure S1A), we found that PAQR4 is up-regulated in all NSCLC cancerous cell lines, with relatively higher expression levels in SPC-A1 and GLC-82 (Figure 1E). Due to the higher expression of PAQR4 in NSCLC cancerous cell lines we hypothesized that PAQR4 might also be frequently mutated in NSCLC. Indeed, we identified many PAQR4 mutations in NSCLC by applying the cBioPortal web resource [38] (Figure 1D; Table 3-4), suggesting that PAQR4 plays potential important role in lung homeostasis.

**PAQR4 knockdown inhibits NSCLC cell proliferation and induces cellular apoptosis**

NSCLC cell lines SPC-A1 and GLC-82 were chosen to further validate the functional roles of PAQR4. We inhibited PAQR4 mRNA expression with two lentivirus shRNAs (Materials and Methods), and verified the inhibition efficiency by real-time RT-PCR (Figure 1F-G). As expected, stable knockdown of PAQR4 inhibited SPC-A1 and GLC-82 cell proliferation and colony formation in vitro, and this effect could be rescued by PAQR4 overexpression (Figure 1H-J and Figure S1D, E, I, J). Indeed, we observed that PAQR4 knockdown significantly decreased the ratio of BrdU-positive cells in SPC-A1 and GLC-82 (Figure 1K-L and Figure S1F-G). Previous findings indicated that PAQR4 promotes cell proliferation by stabilizing CDK4 [33, 34]. However, we analyzed the cell cycle transition by flow cytometry, and did not find significant cell cycle modulation after PAQR4 knockdown, or change in CDK2 and CDK4 protein stabilities (Figure S1H, K), suggesting a cellular context dependent role for PAQR4.

Table 3. PAQR4 mutation information in human NSCLC cancers

| Sample ID | Cancer Study | AA change | Type     |
|-----------|--------------|-----------|----------|
| LUAD-S01315 | Lung Adenocarcinoma (Broad, Cell 2012) | W72C | Missense |
| LUAD-S01315-Tumor | Pan-Lung Cancer (TCGA, Nat Genet 2016) | W72C | Missense |
| TCGA-63-6202-01 | Pan-Lung Cancer (TCGA, Nat Genet 2016) | G178E | Missense |
| TCGA-63-6202-01 | Lymphosquamous Cell Carcinoma (TCGA, Provisional) | G178E | Missense |
| TCGA-63-6202-01 | Lymphosquamous Cell Carcinoma (TCGA, Nature 2012) | G178E | Missense |
| TCGA-63-6202-01 | Lymphosquamous Cell Carcinoma (TCGA, PanCancer Atlas) | G178E | Missense |
| TCGA-56-7579-01 | Pan-Lung Cancer (TCGA, Nat Genet 2016) | L165C>7 | Frame_Shift _Ins |
| TCGA-56-7579-01 | Lymphosquamous Cell Carcinoma (TCGA, PanCancer Atlas) | L165C>7 | Frame_Shift _Ins |
| LUAD-E00697 | Lung Adenocarcinoma (Broad, Cell 2012) | Q241* | None |
| TCGA-37-3789-01 | Lymphosquamous Cell Carcinoma (TCGA, Nat Genet 2012) | R184S | Missense |
| CRUK0001-R1 | Non-Small Cell Lung Cancer (TRACERx, NEJM 2017) | P200A | Missense |
| CRUK0001-R1 | Non-Small Cell Lung Cancer (TRACERx, NEJM 2017) | R184C | Missense |
| CRUK0001-R3 | Non-Small Cell Lung Cancer (TRACERx, NEJM 2017) | R184C | Missense |

Table 4. The cBioPortal database query used in Figure 1D.

| Cancer type | Cancer study | DOI | Journal |
|-------------|--------------|-----|---------|
| LUAD(1)     | Lung Adenocarcinoma (Broad, Cell 2012) | 10.1016/j.cell.2012.08.029 | Cell |
| SCLC        | Small cell lung cancer (Johns Hopkins, Nat Genet 2012) | 10.1038/NG.2405 | Nat Genet* |
| LUSC(1)     | Lung Squamous Cell Carcinoma (TCGA, Nature 2012) | 10.1038/nature11404 | Nature |
| LUSC(2)     | Lung Squamous Cell Carcinoma (TCGA, Provisional) | 10.1038/NG.3564 | Nat Genet* |
| NSCLC       | Pan-lung cancer (TCGA, Nat Genet 2016) | 10.1016/j.cell.2018.02.052 | Cell |
| LUSC(3)     | Lung Squamous Cell Carcinoma (TCGA, PanCancer Atlas) | 10.1016/j.cell.2018.02.052 | NEJM* |
| LUAD(2)     | Lung Adenocarcinoma (TCGA, Provisional) | 10.1038/nature13885 | Nature |
| TRACERx     | Non-Small Cell Lung Cancer (TRACERx, NEJM 2017) | 10.1016/nejm.a161288 | Cell |
| LUAD(3)     | Lung Adenocarcinoma (TCGA, PanCancer Atlas) | 10.1016/j.cell.2018.02.052 | NEJM* |
| LUAD(4)     | Lung Adenocarcinoma (TCGA, Nature 2014) | 10.1038/nature13885 | Nature |

*Nat Genet=National Genetics; *NEJM=The New England journal of medicine
Figure 2. PAQR4 knockdown promotes cisplatin (DDP) induced cellular apoptosis. (A-D) PAQR4 knockdown promotes cisplatin (DDP) induced cellular apoptosis in SPC-A1 (A-B) and GLC-82 (C-D) cells. After 24 h treatment with 8 µM DDP, indicated cells were stained with Annexin V/PI, and the percentage of apoptotic cells was assessed by flow cytometry (A, C). (B) Quantification data for (A). (D) Quantification data for (C). (E-F) Effects of DDP on cellular apoptosis of indicated SPC-A1 (E) and GLC-82 cell lines (F) examined by western blot. 48 h after DDP treatment, indicated total extracts were probed with indicated antibodies: PARP, CC3, Bcl-2, BAX and β-actin. (G-H) PAQR4 knockdown promotes DDP induced cellular apoptosis in A549/DDP cells (G) and SPC-A1/DDP cells (H) detected by SRB assay. (I-J) PAQR4 knockdown promotes DDP induced cellular apoptosis in A549/DDP cells. After 24 h treatment by 20 µM DDP, indicated cells were stained with Annexin V/PI, and the percentage of apoptotic cells were assessed by flow cytometry (I). (J) Quantification data for (I). Means±SEM, * P <0.05; ** P <0.01; *** P <0.001; t-test.

To decipher how PAQR4 regulates cell proliferation without affecting cell cycle transition, we decided to examine the potential role of PAQR4 on regulating cellular apoptosis. Indeed, increased cellular apoptosis in PAQR4 knockdown cells was detected by comparison with that in scramble shRNA control cells (Figure S2A-C). Consistently, increased cisplatin (DDP), Carboplatin (CBP) or Etoposide (ETO) induced cellular apoptosis was observed in PAQR4 knockdown cells, and confirmed by Cleaved Caspase 3 (CC3) and PARP western blot (Figure 2A-F and Figure S2D-F). In vitro, we also found that
PAQR4 is upregulated in cisplatin-resistant A549 (A549/DDP) and SPC-A1 (SPC-A1/DDP) cell lines, whereas knockdown of PAQR4 in both cells inhibited cellular viability (Figure 2G-J and Figure S2G-J). The above data suggest that PAQR4 could be used as a novel therapeutic target in combination with platinum-based chemotherapy in the future.

**Inhibition of xenograft tumor formation in vivo**

To test the potential roles of PAQR4 in vivo, we performed a xenograft tumor formation assay using nude mice. Male nude mice aged 5 weeks were randomly divided into 3 groups, injected with 2 independent PAQR4 stable knockdown cell lines or scramble control shRNA cells (1×10^6 cells/subcutaneously), followed by daily monitoring and weighing every other day. As expected, tumor formation, tumor weights and volumes in PAQR4 knockdown groups were dramatically decreased over the control group (Figure 3A-C and Figure S3A-D). To validate the potential drug resistance role of PAQR4 in vivo, mice were injected with DDP (7 mg/kg) by intraperitoneal injection every 6 days, after xenograft tumors reached about 50 mm³ in size. In line with the findings in vitro, dramatically lower proliferation as measured by Ki67 IHC, and higher overall apoptosis indicated by CC3 IHC, in PAQR4 shRNA tumors were detected (Figure 3D-J).

![Figure 3](http://www.thno.org)

**Figure 3. PAQR4 knockdown inhibits xenograft tumor formation and increases cisplatin sensitivity in vivo.** (A-C) PAQR4 knockdown inhibits xenograft tumor formation in vivo. Representative xenograft tumor images (A), tumor masses (B) and tumor volumes (C) are shown for indicated groups. SPC-A1 cell lines were used. Tumor masses were collected and photographed at the end of the experiment, tumor weights were weighted using electronic scales and tumor volumes measured with a sliding caliper every two days using the formula (L×W^2)/2. (D-G) PAQR4 knockdown increases xenograft tumor sensitivity to cisplatin. Schematic diagram shows the experimental strategy for DDP (7 mg/kg) treatment in nude mice (D). In detail, after xenograft tumors reached about 50 mm³ in size, mice were injected with DDP by intraperitoneal injection every 6 days. At the end of the experiment, representative xenograft tumor images (E), tumor masses (F) and tumor volumes (G) were recorded for the indicated groups. SPC-A1 cell lines were used. (H-J) Representative IHC staining of Ki67 and Cleaved Caspase 3 (CC3) for indicated xenograft tumors after DDP treatment (H). Scale bar: 50 µm. The quantification data for CC3 (I) and Ki67 (J) are included. The percentages of positive cells were counted using Image pro plus 6.0, the percentage of positive cells in every image was calculated using the formula: number of positive cells/total number of cells. Means±SEM, * P <0.05; ** P <0.01; *** P <0.001; t-test.
PAQR4 inhibits Nrf2 degradation by physically interrupting Keap1-Nrf2 complex formation

Antioxidant defense systems regulated by transcription factor Nrf2 has been documented to play an important role in drug resistance mechanisms [39-41]. Based on the established role of PAQR3 in facilitating Keap1-Nrf2 complex formation leading to Nrf2 degradation [31], we hypothesized that PAQR4 might also regulate the Nrf2 protein degradation process. Contrary to PAQR4 high expression in NSCLC, PAQR3 expression was decreased in NSCLC (Figure S4A) [42]. As expected, Nrf2 protein levels were strongly reduced in PAQR4 knockdown cells, which could be reversed by proteasome inhibitor MG132 treatment, whereas the mRNA transcripts of Nrf2 were not regulated by PAQR4 (Figure 4A-B and Figure S4B, D, E), suggesting that PAQR4 inhibits Nrf2 expression at posttranslational level in a ubiquitination-proteasome dependent manner. Consistently, the mRNA expressions of Nrf2 downstream target genes including NADP(H):quinone oxidoreductase 1 (NQO1), glutamate-cysteine ligase catalytic subunit (GCLC), glutamate-cysteine ligase modifier subunit (GCLM), glutathione reductase (GR), thioredoxin reductase (TR) were also decreased upon PAQR4 inhibition (Figure 4D and Figure S4F) [43]. The levels of the nuclear fraction of Nrf2 protein were also significantly reduced by both western blot and immunofluorescence (Figure 4C, E, F, G and Figure S4C, G). In addition, the increased cellular apoptosis in PAQR4 knockdown cells could be rescued by Nrf2 overexpression (Figure S4H-J). Furthermore, we investigated the Nrf2 protein degradation rate, and found that depletion of PAQR4 accelerated Nrf2 degradation in SPC-A1 and GLC-82 cells (Figure 4H-I and Figure S4K-L). Furthermore, PAQR4 overexpression abrogates, whereas its depletion promotes, Nrf2 ubiquitination (Figure 4J-M).

Unlike PAQR3, which is specifically localized in the Golgi apparatus [31], PAQR4 mostly colocalizes with Nrf2 or Keap1 in various cell compartments, and only partially in the Golgi (Figure S5A-C). Since the ubiquitination of Nrf2 is regulated by PAQR4, we speculated that PAQR4 might affect the interaction between Nrf2 and Keap1, the E3 ubiquitin ligase of Nrf2 [41]. Thus, we performed co-immunoprecipitation (co-IP) with cell lysates from Myc-Nrf2 and HA-Keap1 transiently overexpressed HEK-293T, and recapitulated the reciprocal interaction between Nrf2 and Keap1 as documented before (Figure S5D). In addition, the co-IP assay between PAQR4-Flag and Myc-Nrf2/HA-Keap1 validated these interactions (Figure 5A-D). Consistently, we generated and purified the GST-PAQR4 fusion proteins and performed GST pulldown assays, to confirm that GST-PAQR4 binds to the endogenous Nrf2 and Keap1 proteins (Figure 5E). Importantly, the physical interaction between Nrf2 and Keap1 was reduced when PAQR4 was co-expressed in HEK-293T (Figure 5F), suggesting that PAQR4 antagonizes with Keap1 to keep Nrf2 from protein degradation using the ubiquitination-proteasome signaling pathway.

Discussion

Over the last decade, the genetic backgrounds of cancers have been determined and tumors treated in a tailor made fashion. Remarkable advances in the development of predictive biomarkers and specific targeted small molecule inhibitors have led to improvements in some NSCLC patients’ survival rates and quality of life [44]. Unfortunately, there is still no effective biomarker for the majority of NSCLC patients, thus chemotherapy is their first choice treatment option. However, the problem of recurrent drug or chemotherapy resistance remains as a major challenge.

In this study (Figure 5G), we identified that PAQR4, a member of the progestin and adipocytokine receptor (PAQR) family, and also the closest homologue of PAQR3 [25-30], is highly expressed in NSCLC cancerous tissues and cell lines. Its knockdown leads to inhibition of cell proliferation, mainly through inducing cellular apoptosis, both in vivo and in vitro. Importantly, we have shown that PAQR4 competes with Keap1 to interact with and to inhibit Nrf2 protein degradation. This activity is different from the adaptive role of PAQR3 facilitating Keap1-Nrf2 complex formation and protein degradation, and decreased expression of PAQR3 in NSCLC can also lead to chemoresistance by increasing Nrf2 stability [31]. Consistent with this finding, we identified that PAQR3 is decreased in NSCLC. Furthermore, PAQR4 knockdown promotes the sensitivity of cancerous cell to DDP/ Paclitaxel treatment through decreasing Nrf2 protein levels.

The underlying mechanism of why PAQR4 behaves differently from PAQR3 in NSCLC is still unknown, and deciphering the expression regulation of these two family members under different cellular or tissue context might be able to resolve this mystery. For example, the promoter methylation levels or transcriptional regulation mechanisms may be different. Due to lack of commercial or homemade antibodies detecting PAQR4, we were unable to determine the protein expression patterns of PAQR4 both in cancerous tissues or cell lines. Therefore, whether endogenous PAQR4 interacts with Nrf2 and/or how PAQR4 is deregulated at post-translational level in NSCLC need further

http://www.thno.org
characterization. In addition, the physical interacting partners for PAQR3 and PAQR4 could also be different in a context dependent manner. Recent findings showed that PAQR4 promotes cell proliferation and metastasis through CDK4-pRB-E2F1 in NSCLC [33], although we also observed that PAQR4 regulates NSCLC cancerous cell proliferation, we concluded that PAQR4 knockdown inhibits cell proliferation by inducing cellular apoptosis instead of regulating CDK4 protein stabilities. Taken together, our findings identified PAQR4 as a potential therapeutic target for NSCLC treatment in the future.

Figure 4. PAQR4 promotes Nrf2 protein nuclear localization through inhibiting Nrf2 degradation. (A-B) Total Nrf2 proteins were reduced by PAQR4 knockdown in indicated cells (A), which can be reversed by MG132 -proteasome inhibitor (B). Indicated total extracts were probed with Nrf2 and β-actin antibodies. (C) PAQR4 knockdown inhibits nuclear accumulation of Nrf2 proteins in SPC-A1 cells by western blot. Lamin B: nuclear fraction; GAPDH: cytosol fraction. (D) Relative mRNA expression of Nrf2 downstream targeted genes after PAQR4 knockdown by real-time RT-PCR in SPC-A1 cells. (E-G) Representative images of immunofluorescent staining of Nrf2 protein in indicated cell lines (E). (F) is the quantification data for (E) in SPC-A1 cells, (G) Quantification data for immunostaining of Nrf2 in GLC-82 cells. (H-I) Lysates of indicated cell lines treated by cycloheximide (CHX: 100 µg/mL) were examined by western blot with indicated antibodies. (J) Quantification data for (H). The dark arrow heads point to Nrf2 proteins based on previous findings [45]. (J-M) Analysis of Nrf2 ubiquitination upon PAQR4 overexpression or knockdown was examined in indicated cells by western blot with differential antibodies: HA, Myc. Means±SEM, * P <0.05; ** P <0.01; *** P <0.001; t-test.
Figure 5. PAQR4 prevents Nrf2 from ubiquitination by Keap1. (A-B) PAQR4 interacts with Nrf2. HEK-293T cells were transiently transfected with plasmids as indicated. The cell lysates were used for immunoprecipitation (IP) and immunoblotting (IB) using the antibodies as indicated. (C-D) PAQR4 interacts with Keap1. HEK-293T cells were transfected with indicated plasmids and the cell lysates were used for IP and IB. (E) PAQR4 interacts with Nrf2 and Keap1 detected by GST pulldown. Bacterially expressed GST-PAQR4 proteins were purified and detected by Coomassie blue staining. SPC-A1 cell lysates were incubated with GST or GST-PAQR4, and pulldown samples were examined by western blot with indicated antibodies. (F) PAQR4 decreases the interaction of Nrf2 with Keap1. HEK-293T were transfected with indicated plasmids and the cell lysates were used for IP and IB. (G) A model deciphering how PAQR4 promotes chemotherapy resistance mediated by Nrf2. PAQR4 high expression physically competes with Keap1 binding to Nrf2, enhances stabilization and nuclear translocation of Nrf2 proteins, thereby preventing Keap1 mediated ubiquitination and degradation of Nrf2 and resulting in expressions of antioxidant genes and chemotherapy resistance. Means±SEM, *P <0.05; **P <0.01; ***P <0.001; t-test.

Material and Methods

Plasmids construction and cell culture

Independent shRNAs targeting PAQR4 were constructed using a pLKO.1 vector. The two independent PAQR4 targeting sequences are: shRNA#1, 5'-GCAGGCTCCGTCTCATCAC-3'; shRNA#2, 5'-GCTCTTGCTCTGAGAGTTCAA-3'. The pNFE2L2 (NRF2) -ENTER (Gene ID: NM_006164) and pKEAP1-ENTER (Gene ID: NM_203500) plasmids were purchased from Vigene Biosciences Inc., and were sub-cloned into pCDNA3.1. Nrf2 was N-terminal tagged with 6×Myc, and Keap1 was N-terminal tagged with 3×HA. The full length cDNA of PAQR4 (Gene ID: NM_152341.5) was synthesized by Shanghai Generay Biotech, and sub-cloned into pCDH-MSCV-E2F-eGFP lentiviral vector or pCDNA3.1 vector with a 3×Flag at the C-terminus. The lentiviruses were generated according to the manufacturer’s protocol, stable cell lines were generated by lentiviral infection. The BEAS-2B cell line was a gift from Dr. Hongbin Ji at SIBS, CAS, China. HEK-293T was obtained from ATCC. A549, H1299, H1975, H1650 were purchased from Cobioer, China with STR document, BEAS-2B, A549, H1650, H1975, H358, GLC-82 and SPC-A1 cells were cultured in RPMI1640 medium (Corning) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. H1299 and HEK-293T cells were cultured in DMEM medium (Corning).

Immuno-precipitation, immunoblotting and quantitative real-time RT-PCR

To detect the association among PAQR4, Nrf2 and Keap1, indicated constructs were transfected into HEK-293T cells and the cell lysates were subjected to immunoprecipitation with Flag/Myc/HA antibodies.
The precipitated proteins were detected with indicated antibodies by western blot. To detect the ubiquitin-conjugated exogenous Nrf2, the Myc-Nrf2, HA-Ub and PAQR4-Flag constructs were transfected into HEK-293T cells, and exposed to 20 μM MG132 for 9 h prior to lysis. Cell lysates were subjected to immuno-precipitation with Myc antibody and immunoblotting with HA antibody. Indicated cells treated with 100 μg/mL cycloheximide (CHX) were harvested at various time points, and the cell lysates were subjected to western blot. Indicated cells were lysed by RNAiso Plus (Takara Bio, Beijing, China, Cat# 108-95-2). Total RNA was extracted according to the manufacturer’s protocol, and reverse transcribed using a PrimeScript RT reagent Kit (Takara Bio, Beijing, China, Cat# RR047A). Quantitative real-time PCR was performed by FastStart Universal SYBR Green Master Mix (Roche, Cat# 04194194001) using an Applied Biosystems 7500 machine. The primers and antibodies used in this study are shown in Table 5 and 6.

**Cell proliferation, BrdU incorporation, colony formation assays**

Indicated cells were plated onto 12-well plates, the cell numbers were subsequently counted each day using an automatic cell analyzer countstar (Shanghai Ruiyu Biotech Co., China, IC 1000). Cells were cultured in 8-well plates for 24 h, pulsed with 10μM BrdU (Abcam, Cat# ab142567) for 20 min, and fixed with 4% PFA (paraformaldehyde). Cells were then incubated with BrdU (Cell Signaling Technology, Cat# 5292s, dilution 1:1000) primary antibody followed by secondary antibody detection (Abclonal, Cat# 61303, dilution 1:500). Cell nuclei were stained with DAPI (4', 6-diamidino-2-phenylindole). For colony formation assay, indicated cells were seeded in agar medium in 6-well plate with 3×10^3 cells per well supplemented with 2 mL 10% FBS cell culture medium, and the medium changed every 3 days for 2–3 weeks. Indicated cells were fixed with 4% PFA and stained with crystal violet.

**Xenograft tumor formation assay in vivo**

Male nude mice aged 5 weeks were randomly divided into different groups, and were then injected with 2 independent PAQR4 knockdown cell lines or scramble control shRNA cells, (1×10^6 cells/subcutaneously). Nude mice were monitored every day, xenograft tumor weights and volumes were measured with a sliding caliper every two days, and tumor volumes were calculated using the formula (L×W^2)/2. All mice were sacrificed at the end of the experiment and the tumors were harvested and weighted. For the xenograft tumor cisplatin sensitivity assay, when the xenograft tumors reached to 50 mm^3 of volume, the mice were injected with 7 mg/kg DDP by intraperitoneal injection once per week. Four weeks later, all mice were sacrificed at the end of the experiment and the tumors were harvested and weighted.

**SRB and drug sensitivity assays**

Cells were plated into 96-well plates with 1×10^4 cells per well and cultured overnight, indicated drugs were added. Cell viabilities were detected by sulforhodamine B (SRB) staining following a standard protocol. The assay was repeated in triplicate. Cells were plated into 6 cm culture dishes with 5×10^5 cells per dish and cultured overnight, indicated drugs were added for 48 h. The apoptotic cell numbers were analyzed by flow cytometry. Indicated cell lysates were detect by antibodies against apoptotic markers by western blot.

**Table 5. Primer sequences used in this study.**

| Name                  | Primer (5’-3’)                       |
|-----------------------|--------------------------------------|
| human PAQR4_QPCR_F    | CGAACTGCGAAGACACATCTACA             |
| human PAQR4_QPCR_R    | AGGCTGTTGACAAGCGAGAC                 |
| human Actin_qPCR_F    | AAGTGTCACTGGAACACATCGG              |
| human Actin_qPCR_R    | CCGACTGCTCATATCCTCTGCT               |
| human Nrf2_qPCR_F     | TCCCCCATGAGTGTCGAAA                  |
| human Nrf2_qPCR_R     | CAACAGGGGGTTGAATGTTTT               |
| human GCCL_qPCR_F     | ATGGCATGGGATTGGAA                    |
| human GCCL_qPCR_R     | AGATATGCTGAGCTGGAGATG               |
| human GCLM_qPCR_F     | GACCAAAACAGATGGAGACAGAC             |
| human GCLM_qPCR_R     | CAGTCTAATGCTGTGGGTC                 |
| human GR_qPCR_F       | CAGCGGAGACCTGGAGAAC                 |
| human GR_qPCR_R       | CGACAAAGTCTTTTAAACTCCTTT            |
| human TR_qPCR_F       | CAGACGGGAGCGTCGGTC                 |
| human TR_qPCR_R       | CAGCGGAGCGTCGGTC                 |
| human NQO1_qPCR_F     | ATGTAGCATCAAAGCGACCCCTTCC           |
| human NQO1_qPCR_R     | TCCCTTCAGAAGCTACGTACG               |
| human PAQR4_qPCR_F    | AAACCCTACATCCGACG                 |
| human PAQR4_qPCR_R    | TCTGGACGGACCTGGTGGG                |

**Table 6. Antibodies used in this study.**

| Name | Catalog number | Dilution | Supplier | species |
|------|---------------|----------|----------|---------|
| CDK2 | 10122-1-AP    | 1:1000   | Proteintech | Rabbit |
| CDK4 | ab108357      | 1:1000   | abcam    | Rabbit |
| LaminB | ab16648     | 1:2000   | abcam    | Rabbit |
| β-actin | 60004-1-1g | 1:5000   | Proteintech | Mouse |
| GAPDH | 60004-1-1g   | 1:10000  | Proteintech | Mouse |
| PARP | 95425         | 1:500    | CST      | Rabbit |
| Cleaved Caspase3 | 9661S   | 1:500    | CST      | Rabbit |
| Bcl-2 | 150715       | 1:100    | CST      | Mouse |
| Bax | ab77556       | 1:1000   | abcam    | Mouse |
| Brodu | 5292         | 1:100    | CST      | Mouse |
| Nfr2 | ab62352       | 1:1000   | abcam    | Rabbit |
| Flag | 14793         | 1:1000   | CST      | Mouse |
| Flag | 1804          | 1:1000   | sigma    | Mouse |
| Myc | sc-40         | 1:1000   | santi cruz | Mouse |
| Myc | sc-789        | 1:1000   | santi cruz | Rabbit |
| HA  | sc-7392       | 1:1000   | santi cruz | Mouse |
| PAQR4 | 13401-1-AP  | 1:1000   | Proteintech | Rabbit |
Immunofluorescence and Immunohistochemistry staining

To detect the co-localization of PAQR4 with Nrf2 or Keap1, indicated constructs were transfected into SPC-A1 cells, and the cells were seeded into 8-well plates with 5×10^4 cells per well. 48 h after transfection, indicated cells were fixed with 4% paraformaldehyde for 20 min at room temperature, permeated with 0.2% Triton X-100 for 5 min, followed by primary and secondary antibody staining. Cells were again washed, mounted, air-dried, and then visualized by Nikon A1 confocal microscopy. For IHC staining, tumor sections were incubated with 3% hydrogen peroxide, blocked with 10% goat serum in 0.2% Triton X-100 containing PBS (phosphate buffer saline) and followed by primary antibody incubation. The biotin conjugated secondary antibody detection was performed at room temperature for 40 min, followed by primary antibody incubation. The biotin conjugated secondary antibody detection was performed at room temperature for 40 min, followed by diaminobenzidine (DAB) staining. Images were captured using a binocular Nikon research light microscope (ECLIPSE, Nikon) in bright field. The percentage of positive cells was counted using Image pro plus 6.0, and the percentage of positive cells in each image was calculated using the following formula: number of positive cells/number of all cells.

Supplementary Material
Supplementary figures. http://www.thno.org/v10p3767s1.pdf

Acknowledgments
This study was supported by the National Key Research and Development Program of China, Stem Cell and Translational Research (to Y.B.C., 2016YFA0100900). This work was also supported by National Nature Science Foundation of China (U1902216, 81772996, 81672764, 81802802, 81972181), Yunnan Applied Basic Research Projects (2019J009, 2019FB106, 2019FB111) and AMHD-2019-6. C.P.Y was also supported by Youth Innovation Promotion Association, CAS; the youth talent support program of Yunnan Province; Project of Innovative Research Team of Yunnan Province (2019HC005). L.P.J was also supported by Western Light Program, CAS.

Author contribution
Y.B.C. and C.P.Y supervised and wrote the manuscript. P.F.X., L.P.J. and Y.Y. designed the functional analysis for PAQR4 in NSCLC. M.G.W performed the IHC analysis. B.Y.L., Y.L.S., Q.S.S., X.L.J., Y.M.H., D.T.C., Q.X.X., Z.Z.Y., L.C.D., J.L. and S.Z. performed most biochemical experiments. P.S. provided help for the bioinformatic studies and discussion. We thank Drs. Nigel Fraser and Jumin Zhou for their instructive comments on the manuscript.

Competing Interests
The authors have declared that no competing interest exists.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7-34.
2. Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019; 19:9-31.
3. Leon G, MacDonagh L, Finn SP, Cuffe S, Barr MP. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. Pharmacol Ther. 2016; 158: 71-90.
4. Azzoli CG, Baker S Jr., Tenini S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009; 27: 6251-66.
5. Gower A, Wang Y, Giaccione G. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J Mol Med (Berl). 2014; 92: 697-707.
6. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010; 49: 1603-16.
7. Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets. 2006; 6: 295-311.
8. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5: 219-34.
9. Zhang X, Qi Z, Yin H, Yang G. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1alpha-mediated regulation of apoptosis and autophagy. Theranostics. 2019; 9: 1096-114.
10. Sau A, Pellizzari Tregno F, Valentino F, Federici G, Caccari AM. Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys. 2010; 500: 116-22.
11. Kansanen E, Kuusmanen SM, Leinonen H, Levonen AL. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 2013; 1: 45-9.
12. Takaya K, Suzuki T, Motohashi H, Ohoeda K, Satomi S, Kessler TW, et al. Validation of the multiple sensor mechanism of the Keapl-Nrf2 system. Free Radic Biol Med. 2012; 53: 817-27.
13. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013; 27: 2179-91.
14. Feng L, Li J, Yang L, Zha L, Huang X, Zhang S, et al. Tamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasia. Theranostics. 2017; 7: 1890-900.
15. Kim YK, Oh JE, Kim MS, Kang MR, Park SW, Han JY, et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol. 2010; 220: 446-51.
16. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006; 3: e420.
17. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A. 2008; 105: 13568-73.
18. Solis LM, Behrens C, Dong W, Suzaarik M, Osburn NC, Moran CA, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010; 16: 3743-53.
19. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun. 2008; 375: 19-31.
20. Cho JM, Manandhar S, Lee HR, Park HM, Kwak MK. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 2008; 260: 96-108.
21. Li QC, He YH, Wu H, Yang CP, Pu SY, Fan SQ, et al. A Normalization-Free and Nonparametric Method Sharpens Large-Scale Transcriptome Analysis and Reveals Common Gene Alteration Patterns in Cancers. Theranostics. 2017; 7: 2888-99.
22. Tang YT, Hu T, Arterburn M, Boyle B, Bright JM, Emtage PC, et al. PAQR proteins: a novel membrane receptor family defined by an ancient 7-transmembrane pass motif. J Mol Biol. 2005; 357: 2888-99.
23. Zhang X, Qi Z, Yin H, Yang G. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1alpha-mediated regulation of apoptosis and autophagy. Theranostics. 2019; 9: 1096-114.
25. Wang X, Li X, Fan F, Jiao S, Wang L, Zhu L, et al. PAQR3 plays a suppressive role in the tumorigenesis of colorectal cancers. Carcinogenesis. 2012; 33: 2228-35.

26. Ling ZQ, Guo W, Lu XX, Zhu X, Hong LL, Wang Z, et al. A Golgi-specific protein PAQR3 is closely associated with the progression, metastasis and prognosis of human gastric cancers. Ann Oncol. 2014; 25: 1363-72.

27. Wu HG, Zhang WJ, Ding Q, Peng G, Zou ZW, Liu T, et al. Identification of PAQR3 as a new candidate tumor suppressor in hepatocellular carcinoma. Oncol Rep. 2014; 32: 2687-95.

28. Ma Z, Wang Y, Piao T, Li Z, Zhang H, Liu Z, et al. The tumor suppressor role of PAQR3 in osteosarcoma. Tumour Biol. 2015; 36: 3319-24.

29. Li Z, Ling ZQ, Guo W, Lu XX, Pan Y, Wang Z, et al. PAQR3 expression is downregulated in human breast cancers and correlated with HER2 expression. Oncotarget. 2015; 6: 12357-68.

30. Wu Q, Zhaaung K, Li H. PAQR3 plays a suppressive role in laryngeal squamous cell carcinoma. Tumour Biol. 2015.

31. Zhang Y, Hou Y, Liu C, Li Y, Guo W, Wu JL, et al. Identification of an adaptor protein that facilitates Nrf2-Keap1 complex formation and modulates antioxidant response. Free Radic Biol Med. 2016; 97: 38-49.

32. Wang L, Zhang R, You X, Zhang H, Wei S, Cheng T, et al. The steady-state level of CDK4 protein is regulated by antagonistic actions between PAQR4 and SKP2 and involved in tumorigenesis. J Mol Cell Biol. 2017; 9: 409-21.

33. Wu B, Liu R. PAQR4 promotes cell proliferation and metastasis through the CDK4-pRB-E2F1 pathway in non-small-cell lung cancer. Onco Targets Ther. 2019; 12: 3625-33.

34. Zhang H, Han R, Ling ZQ, Zhang F, Hou Y, You X, et al. PAQR4 has a tumorigenic effect in human breast cancers in association with reduced CDK4 degradation. Carcinogenesis. 2018; 39: 439-46.

35. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45: W98-W102.

36. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Perico-Rodriguez J, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19: 649-58.

37. Gyorffy B, Surovick P, Budczies J, Lanczyk A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013; 8: e82241.

38. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cbioPortal. Sci Signal. 2013; 6: p31.

39. Paulsen CE, Carroll KS. Cysteine-mediated redox signaling: chemistry, biology, and tools for discovery. Chem Rev. 2013; 113: 4633-79.

40. Yates MS, Kensler TW. Chemopreventive promise of targeting the Nrf2 pathway. Drug News Perspect. 2007; 20: 109-17.

41. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal. 2010; 13: 1665-78.

42. Li X, Li M, Chen D, Shi G, Zhao H. PAQR3 inhibits proliferation via suppressing PI3K/AKT signaling pathway in non-small cell lung cancer. Arch Med Sci. 2018; 14: 1289-97.

43. Chen Q, Peng H, Dong L, Chen L, Ma X, Peng Y, et al. Activation of the Nrf2-ARE signalling pathway by the Lentinula edodes polysaccharose LNT alleviates ROS-mediated cisplatin nephrotoxicity. Int Immunopharmacol. 2016; 36: 1-8.

44. Thomas A, Liu SV, Subramaniam DS, Gáncorze G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol. 2015; 12: 511-26.

45. Pi J, Bai Y, Reece JM, Williams J, Liu D, Freeman ML, et al. Molecular mechanism of human Nrf2 activation and degradation: role of sequential phosphorylation by protein kinase CK2. Free Radic Biol Med. 2007; 42: 1797-806.